Ads
related to: pembrolizumab clinical trials- Side Effects
Learn About Possible Side Effects
at the Official Patient Site.
- What Is KEYTRUDA?
Learn About What KEYTRUDA Is & How
It May Help Eligible Patients.
- Clinical Trial Results
See Clinical Trial Results
at the Official Site.
- Taking KEYTRUDA?
Learn What to Expect When
Taking KEYTRUDA.
- Treatment Options
Learn About Treatment
Options With KEYTRUDA.
- Get Financial Help
Find Assistance and Payment
Information for Eligible Patients.
- Side Effects
Search results
Earnings call: AIM ImmunoTech highlights Q1 2024 progress on cancer trials
Investing.com· 6 days agoAIM ImmunoTech (NYSE: AIM ) Inc. (NYSE American: AIM) provided an optimistic update during its first...
Earnings call: Compugen outlines progress and plans in Q1 2024 earnings By Investing.com
Investing.com· 1 day agoThe company highlighted its successful transition of AI-predicted drug targets to clinical trials...
Earnings call: BioAtla reports promising data in cancer drug trials By Investing.com
Investing.com· 7 days agoBioAtla, a biotechnology company, has announced its first-quarter financial results and provided a...
Does AI Really Make Moderna Stock (NASDAQ:MRNA) a Buy?
TipRanks via Yahoo Finance· 4 days agoHowever, the company is once again on the move — in a good way. The stock is up 68% over the past...
Immutep shares gain as CapitalOne sets $10 target on cancer drug potential By Investing.com
Investing.com· 4 days agoOn Friday, Immutep Limited (NASDAQ:IMMP) received a positive assessment from CapitalOne, as the firm...
AIM ImmunoTech Inc (AIM) (Q1 2024) Earnings Call Transcript High
Guru Focus· 6 days agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. AIM ImmunoTech Inc reported positive safety and tolerability results from the Duripanc study ...
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
GuruFocus.com via Yahoo Finance· 7 days agoA: (Richard Waldron, CFO) The monotherapy trial included a broad range of melanomas and relapsed refractory carcinomas. We have treated three patients at the one gram dosing ...
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
InvestorPlace· 5 days agoPenny stocks to buy understandably offer many enticing attributes, not least of which is the...
Third Party Withdraws Appeal Related to Cantargia Patent
Morningstar· 6 days agoLUND, SWEDEN / ACCESSWIRE / May 16, 2024 / Cantargia (STO:CANTA) (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that the Notice of Appeal filed with respect to one of Cantargia's granted ...
Atezolizumab Plus Chemo Falters in Rapidly Relapsing TNBC
MedPage Today· 6 days agoMedian OS was 12.1 months with atezolizumab plus chemotherapy compared with 11.2 months with...
Ads
related to: pembrolizumab clinical trials